N/A
Completed N=42
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
Source: ClinicalTrials.gov NCT00976950 ↗Enrolled (actual)
42
Serious AEs
2.4%
Results posted
Aug 2012
Primary outcomePrimary: Number of Patients Reporting Adverse Events (AE) — 6; 1; 4; 1 Participants
Summary
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Reporting Adverse Events (AE) |
6; 1; 4; 1; 2 | — |
| SECONDARY Virologic Response |
0; 4; 38 | — |
| SECONDARY Change in CD4+ Cell Count From Baseline at Week 48 |
85.8 | — |
Eligibility Criteria
Inclusion criteria
- HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options.
- The inclusion criteria follow the same criteria which are describe in the newest SPC
Exclusion criteria
The exclusion criteria follow the same criteria which are describe in the newest SPC
Data sourced from ClinicalTrials.gov (NCT00976950). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.